Top stock stories from Wednesday: Microsoft hits milestone valuation, Amazon details green strategy, Shake Shack expands in China

U.S. FDA struggles with Biogen’s Alzheimer drug’s approval The U.S. Food and Drug Administration (FDA) met with disagreements within the agency regarding approval of Biogen’s Alzheimer’s drug, Aduhelm, documents published on Tuesday revealed. Following expedited approval of the drug on 7th June, some members of FDA’s independent advisory panel fiercely criticised the decision, with three […]